These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25076257)

  • 1. Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report.
    Biasco E; Antonuzzo A; Cianci C; Derosa L; Marconcini R; Farnesi A; Galli L
    Tumori; 2014; 100(3):e83-6. PubMed ID: 25076257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
    Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
    Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of patients with metastatic renal cell carcinoma treated with pazopanib in daily clinical practice: a single institution experience.
    Ricotta R; Di Bella S
    Tumori; 2014; 100(3):e87-91. PubMed ID: 25076258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
    Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
    Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with pazopanib in the treatment of metastatic renal cell carcinoma: a monocentric experience.
    Gernone A
    Tumori; 2014; 100(4):165e-8e. PubMed ID: 25296611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].
    Büchler T; Finek J; Hájek J; Kocák I; Kubácková K; Lakomý R; Melichar B; Petruzelka L; Poprach A; Siffnerová M; Tomásek J; Vyzula R; Zemanová M;
    Klin Onkol; 2013; 26(1):55-7. PubMed ID: 23607143
    [No Abstract]   [Full Text] [Related]  

  • 9. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
    Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
    BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib.
    Jebb A; Hadden P; Broom RJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):e143-6. PubMed ID: 24656526
    [No Abstract]   [Full Text] [Related]  

  • 11. Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.
    Ratta R; Santini D
    Tumori; 2014; 100(2):e59-62. PubMed ID: 24852879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment.
    Kok VC; Kuo JT
    BMC Urol; 2016 Jul; 16(1):34. PubMed ID: 27377922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term response to pazopanib in an elderly man with mRCC. A case report.
    D'Aniello C; Cavaliere C; Pisconti S; Facchini G
    Tumori; 2014; 100(6):e305-8. PubMed ID: 25688517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in renal carcinoma: a case of long-term effect with complete control of toxicity.
    Conforti S; Ceniti S; Conforti L; Turano S; Minardi S; Palazzo S
    Tumori; 2014; 100(6):e293-7. PubMed ID: 25688514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.
    Masini C; Vitale MG; Maruzzo M; Procopio G; de Giorgi U; Buti S; Rossetti S; Iacovelli R; Atzori F; Cosmai L; Vignani F; Prati G; Scagliarini S; Guida A; Berselli A; Pinto C
    Clin Genitourin Cancer; 2019 Feb; 17(1):e150-e155. PubMed ID: 30396828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
    Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
    Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.